Table 1. A comparison of the potency of SARS-CoV-2 antivirals by a CPE-based cell viability assay.

	EC50 against SARS-CoV-2 Delta
	293 T-hACE2-TMPRSS2	Vero-TMPRSS2	Vero-TMPRSS2 with CP-100356
S-217622 (nM)	26 ± 6.65	407 ± 21.3	69 ± 11.2
Nirmatrelvir (nM)	37 ± 5.30	>1000	132 ± 32.0
NHC (nM)	538 ± 142	360 ± 49.4	677 ± 8.89
Molnupiravir (nM)	3675 ± 1093	3169 ± 217	2280 ± 118
Remdesivir (nM)	<3.9	>500	32 ± 4.52